Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: SSP-002358 (0.1 mg) + PPI
DRUG: SSP-002358 (0.5 mg) + PPI
DRUG: SSP-002358 (2.0 mg) + PPI
DRUG: Placebo + PPI

Sponsor

Shire